Bedrijfsberichten · 22-10-20261 min lezen

HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial

Lokale automatische vertaling · Oorspronkelijke brontaal

Samenvatting

Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progress…

Oorspronkelijke brontaal: PR Newswire — Global News ReleasesOrigineel bericht openen →

Meer inzichten

Zakelijke inzichten →

HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026

Hansa Biopharma kondigt positieve resultaten van Idefirix PAES aan die werden gepresenteerd in de sessie High-Impact Clinical Trials op ASN Kidney Week.